PRESS RELEASE : Adrenomed Supervisory Board appoints Dr. Wolfgang Baiker as CEO

 
 DGAP-News: Adrenomed AG / Key word(s): Personnel 
Adrenomed Supervisory Board appoints Dr. Wolfgang Baiker as CEO 
 
2021-01-04 / 09:30 
The issuer is solely responsible for the content of this announcement. 
 
*Adrenomed Supervisory Board appoints Dr. Wolfgang Baiker as CEO* 
 
*- Former CEO of Boehringer Ingelheim USA Corp. to accelerate Adrenomed's 
development of Adrecizumab in septic shock * 
 
*Hennigsdorf/Berlin (Germany), January 04, 2021 - *Adrenomed AG, the 
vascular integrity company, announced today that its Supervisory Board has 
appointed Dr. Wolfgang Baiker as Chief Executive Officer (CEO) effective 
January 1, 2021. 
 
Dr. Baiker provides over 30 years of experience in the pharmaceutical and 
biotechnology industry, and until his recent retirement served as President 
and CEO of Boehringer Ingelheim USA. Previously, he held various roles at 
Boehringer Ingelheim, including Head of Global Development, Head of Global 
Manufacturing and Global Quality, as well as Head of the Biopharmaceutical 
Business Unit. Currently, Dr. Baiker is a Venture Partner with Wellington 
Partners, chairs the Board of Trustees of the Max Planck Institute of 
Polymer Research and sits on multiple boards of biopharmaceutical start-up 
companies. Dr. Baiker studied medicine at the Universities of Bochum, 
Berlin, Ulm, Sheffield and Munich and obtained his Ph.D. from the University 
of Ulm and an MBA from Pace University in New York. 
 
Dr. Bernd Wegener, Chairman of Adrenomed's Supervisory Board, said: "It is a 
true pleasure to welcome Dr. Wolfgang Baiker as CEO of Adrenomed. From his 
extraordinary career and exacting decision-making roles, Dr. Baiker brings a 
wealth of experience along the pharmaceutical value chain. He is highly 
respected in both the European markets and the US, where he has built a rare 
track record of success and where he has a very thorough senior level 
network." 
 
"I have been impressed by the results of Adrenomed's Phase II study 
evaluating Adrecizumab in septic shock. Adrenomed has built a strong, 
biomarker-guided therapeutic approach based on a unique mode of action 
addressing the loss of vascular integrity as a major cause of mortality in 
sepsis," said Dr. Wolfgang Baiker. "It is an exciting opportunity to be 
offered the responsibility to lead the company through the next stages in 
the development of an urgently needed therapeutic to treat sepsis and septic 
shock." 
 
*About Adrenomed* 
 
Adrenomed AG is a German privately financed, clinical-stage 
biopharmaceutical company. Adrenomed's mission is to rescue vascular 
integrity in order to save the lives of critically ill patients with limited 
treatment options. Founded in 2009 by a management team with decades of 
in-depth experience in sepsis and deep knowledge in diagnostics and drug 
development, the company's lead product candidate Adrecizumab is a 
first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective 
peptide Adrenomedullin, an essential regulator of vascular integrity. 
Adrecizumab has successfully completed a biomarker-guided, double-blinded, 
placebo-controlled, randomized, multicenter proof-of-concept Phase II trial 
with 301 patients suffering from septic shock. For further information, 
please visit www.adrenomed.com [1] and follow us on LinkedIn [2] and Twitter 
[3]. 
 
*Contact                            *Media Inquiries 
 
Adrenomed AG*                       MC Services AG* 
Frauke Hein, Ph.D. (Chief Business  Eva Bauer / Julia von Hummel 
Officer)                            phone: [phone] 
phone: [phone]          [e-mail] 
[e-mail] 
 
2021-01-04 Dissemination of a Corporate News, transmitted by DGAP - a 
service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
 
The DGAP Distribution Services include Regulatory Announcements, 
Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
1157935 2021-01-04 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=8f59fc240bf76f0ec823a649930a706a&application_id=1157935&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=03206e95d8a350115a5e89184c3c27bc&application_id=1157935&site_id=vwd&application_name=news 
3: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=87a47988159cd610be0cf570963cd650&application_id=1157935&site_id=vwd&application_name=news

(END) Dow Jones Newswires

January 04, 2021 03:30 ET (08:30 GMT)